Drug: Acarbose

What It Is

Acarbose is an oral type 2 diabetes drug in use since the 1990s. It belongs to a small class called alpha-glucosidase inhibitors. These act inside the small intestine and are barely absorbed into the body, so most of its effect and most of its side effects stay in the gut. For much of its history it was a second-line drug, used when the main problem was high blood sugar after meals. It is common in parts of East Asia, where diets are high in starch, and it is inexpensive and off-patent.

Aging researchers later took an interest for a different reason than blood sugar. A 2014 report from a program that tests drugs for lifespan in genetically diverse mice found acarbose extended their lives. That result put it on lists of candidate longevity drugs.

What It Does

In type 2 diabetes, acarbose lowers HbA1c by about 0.8 percentage points, a modest drop, weaker than metformin at usual doses. Almost all of it comes from the smaller after-meal glucose rise. In prediabetes, the STOP-NIDDM trial found it cut progression to type 2 diabetes by about a quarter over roughly three years. Type 2 diabetes is largely a diet-driven disease, built over years on refined and ultra-processed carbohydrate. In the Diabetes Prevention Program, lifestyle change alone cut progression by 58%, against 31% for metformin.

STOP-NIDDM also reported a striking drop in cardiovascular events. That result came from just a handful of events and drew heavy criticism. The ACE trial was built to settle the question, in more than 6,000 people who had coronary heart disease and prediabetes. It found no cardiovascular benefit, though it confirmed the diabetes-prevention effect.

The National Institute on Aging Interventions Testing Program runs the same test across three independent laboratories to weed out flukes. In that program, acarbose extended mouse median lifespan by about 22% in males and about 5% in females. A higher-dose study repeated the male-biased pattern. Why the effect favors males is unknown. Researchers suspect it comes from how males and females process the drug and its effects on the gut, though no mechanism is established.

No completed human study shows acarbose extends healthy lifespan or healthspan, and there is no established dose for that use.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Blood Sugar

Lowers HbA1c about 0.8 percentage points in type 2 diabetesModerate

In plain terms

Acarbose lowers long-term blood sugar in type 2 diabetes by a bit under one percentage point of HbA1c, a modest drop.

In detail

In a Cochrane review of alpha-glucosidase inhibitors in type 2 diabetes, acarbose lowered HbA1c by about 0.8 percentage points versus placebo, a smaller reduction than metformin typically produces, acting mainly by blunting the post-meal glucose rise. Measured in: Pooled randomized trials of acarbose and other alpha-glucosidase inhibitors in adults with type 2 diabetes.. The pooled trials varied in dose, duration and diet, and many were short; the glycemic effect is smaller than that of first-line drugs.

The study · 1

Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review) · Cochrane Database Syst Rev 2005

Cut progression from prediabetes to diabetes about 25% over 3.3 years (STOP-NIDDM)Moderate

In plain terms

In people with prediabetes, acarbose cut the rate of developing type 2 diabetes by about a quarter over roughly three years.

In detail

In the STOP-NIDDM trial, acarbose reduced the relative risk of progressing from impaired glucose tolerance to type 2 diabetes by about 25% (hazard ratio 0.75) over a mean 3.3 years versus placebo. Measured in: 1,429 adults with impaired glucose tolerance, randomized to acarbose or placebo, mean follow-up 3.3 years.. A high dropout rate, largely from gastrointestinal side effects, complicated the analysis, and some diabetes diagnoses appeared soon after acarbose was stopped.

The study · 1

Chiasson et al., acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial · Lancet 2002

The same ACE trial cut new diabetes about 18%Moderate

In plain terms

The same large trial that found no heart benefit did confirm that acarbose reduced the onset of diabetes.

In detail

In the same ACE trial, acarbose reduced the incidence of new type 2 diabetes by about 18% (rate ratio 0.82) versus placebo, confirming a diabetes-prevention effect of similar size to STOP-NIDDM. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, median follow-up 5 years.. The absolute reduction was modest and this population already had coronary disease, so the prevention benefit should be read alongside the drug tolerability.

The study · 1

Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Heart And Vascular

No reduction in cardiovascular events in the larger ACE trial (hazard ratio 0.98)Moderate · no effect

In plain terms

In a large trial built to test it, acarbose did not lower the rate of heart attacks, strokes or cardiovascular death.

In detail

In the ACE trial, acarbose did not reduce the primary composite of major cardiovascular events (hazard ratio 0.98) in Chinese adults with coronary heart disease and impaired glucose tolerance over a median 5 years. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, randomized to acarbose or placebo, median 5 years.. The trial was in an East Asian population with established coronary disease, so it does not rule out a different effect in other groups, but it directly contradicts the earlier cardiovascular signal.

The study · 1

Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

STOP-NIDDM hinted at 49% fewer cardiovascular events, from very few eventsPreliminary

In plain terms

An early trial hinted acarbose might reduce heart events in prediabetes, but the signal came from very few events and was not convincing on its own.

In detail

A secondary analysis of STOP-NIDDM reported that acarbose was associated with a 49% relative reduction in cardiovascular events and fewer myocardial infarctions, but the finding rested on a small number of events and was widely criticized. Measured in: 1,429 adults with impaired glucose tolerance in STOP-NIDDM; cardiovascular events were a secondary endpoint with few total events.. The cardiovascular result was a secondary endpoint based on a handful of events (for example one versus twelve myocardial infarctions), and a later dedicated trial did not confirm it.

The study · 1

Chiasson et al., acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial · JAMA 2003

Longevity And Mortality

Extended median lifespan about 22% in male mice, about 5% in femalesPreliminary

In plain terms

Acarbose made mice live longer, with a much bigger effect in males than females, in a careful multi-laboratory study.

In detail

In the NIA Interventions Testing Program, acarbose added to the diet from 4 months of age (young adulthood) extended median lifespan by about 22% in male genetically diverse mice and about 5% in females, a sex-biased effect seen across three independent laboratories. This is an animal result in mice, and the strong sex difference is unexplained; it cannot be read straight across to people.

The study · 1

Harrison et al., acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males · Aging Cell 2014

Higher doses raised male mouse lifespan 16% or 17%, females 4% or 5%Preliminary

In plain terms

A second mouse study at higher doses again extended male lifespan more than female, by about 16% or 17% in males, and it still worked when treatment began later in life.

In detail

A follow-up Interventions Testing Program study tested acarbose at three doses and found the two higher doses raised male mouse median lifespan by 16% or 17% and female median lifespan by 4% or 5%, replicating the male-biased benefit even when treatment began later in life. This remains a mouse result; the replicated sex difference and the reliance on continuous dietary dosing limit how far it can be carried to humans.

The study · 1

Harrison et al., acarbose improves health and lifespan in aging HET3 mice · Aging Cell 2019

How it works

Gut fermentation and short-chain fatty acids: a proposed mouse longevity mechanismPreliminary · mixed

In plain terms

In mice, acarbose changed the gut bacteria and increased helpful fermentation products, and those changes lined up with how much longer the mice lived.

In detail

In mice, acarbose shifted the composition of the gut microbiome and raised levels of short-chain fatty acids such as butyrate and propionate, and the degree of these changes tracked with the lifespan extension, suggesting colonic fermentation is part of the mechanism. This is a correlation within mouse studies between microbiome changes and lifespan, not proof that the short-chain fatty acids cause the longevity effect.

The study · 1

Smith et al., changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice · BMC Microbiol 2019

Anatomy

1A gut-acting drug

Acarbose is an alpha-glucosidase inhibitor, taken by mouth with the first bite of a meal, so it is in place as the carbohydrate arrives.

2How it blunts the sugar spike

Enzymes in the intestinal wall normally break starch and sucrose into glucose so it can be absorbed. Acarbose slows those enzymes, so carbohydrate is digested more gradually and glucose enters the blood more slowly. The result is a lower, flatter rise in blood sugar after a meal. That is where the drug does most of its work on blood sugar.

3The carbohydrate that reaches the colon

Because some carbohydrate is not broken down in the small intestine, more of it passes into the colon, where gut bacteria ferment it. That fermentation produces short-chain fatty acids such as butyrate, and it also produces the gas that is its main side effect. The same fermentation is one of the mechanisms researchers suspect in the animal longevity findings.

How to Approach It

These steps run from the foundations that help anyone down to the animal findings still confined to the lab.

1

Start with the basics a pill does not replaceFreeModerate

Eating fewer refined carbohydrates, walking after meals, and building muscle that takes up glucose all lower the same after-meal glucose rise the drug targets. These foundations carry far stronger evidence for metabolic health and healthy aging than any longevity drug. See [resistance training](/go/integrative/practice/resistance-training) for holding muscle with age.

2

For diabetes or prediabetes, this is where the evidence is solidLowEasy

The diabetes and prediabetes evidence above is the solid part: acarbose suits people whose blood sugar spikes mainly after meals, and it is inexpensive. Whether it fits your blood sugar, your other medicines, and your tolerance for its gut effects is a conversation with a prescriber.

3

Treat the longevity question as a mouse resultFreeEasy

The animal findings are what put acarbose on longevity forums, and human data will decide whether they carry over. Following that research as it appears is free. The drug itself is a prescription decision, and a clinician can weigh it against the gut side effects.

Go Deeper

• The biology of aging: where nutrient handling and the gut sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
• Insulin and glucose handling: the metabolic system acarbose acts on, and why flattening the after-meal glucose rise matters.
• Metformin: the other cheap diabetes drug at the center of the longevity question, with a stronger glycemic record and the same gap between hint and proof.
• Berberine: the plant compound often sold as a natural blood-sugar agent, and what its evidence shows.

The Chinese Medicine View

Acarbose comes from modern pharmacology, so the tradition never named it. But it acts on ground Chinese medicine mapped long ago: digestion. The Spleen and Stomach, in this framework, govern the transformation and transport of food into usable substance. When rich or excessive eating overwhelms that work, the tradition describes food stagnating and turning to Dampness and Phlegm. Those patterns are often mapped onto the modern picture of insulin resistance and the excess weight of type 2 diabetes. A drug that slows the breakdown of a heavy starchy meal works in that same territory.

The tradition points in two directions here. Yang Sheng advises eating in moderation and not overwhelming the digestion: advice that lines up with a drug meant to ease a large carbohydrate load. Yet the same framework holds that the Spleen dislikes Dampness and stagnation. In these terms, a drug that leaves carbohydrate to ferment and produce gas creates the same fullness the tradition tries to relieve. That the drug's most common real-world complaint is bloating is an ironic echo, not evidence that the Damp-Phlegm model predicted it. Its place in type 2 diabetes care comes from the randomized trials above.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Gas, bloating and diarrhea are the main reason people stop acarbose

Across the trials pooled in the Cochrane review, acarbose caused substantially more flatulence, bloating and diarrhea than placebo, and these gastrointestinal effects were the main reason participants stopped the drug. The side effects are dose-related and often ease with a slow increase, but they drive high discontinuation rates and complicated the trials.Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review)

A prescription drug, and the decision sits with a clinician

Acarbose is a prescription medicine. Whether it fits, at what dose, and how fast to build up depends on your blood sugar, your digestion, your other conditions and other medicines. Starting, changing or stopping it belongs with a prescriber. No safe general dose exists for a healthy person outside diabetes care.

Gas, bloating and diarrhea are the usual limit

Because acarbose leaves carbohydrate to ferment in the colon, flatulence, bloating, abdominal discomfort and diarrhea are common, especially early and after high-starch meals. These are the main reason people stop the drug. They often ease with a slow dose increase and tend to lessen over weeks, but for many people they are the deciding factor.

Bowel and digestive conditions are a boundary

Acarbose is not appropriate in inflammatory bowel disease, significant intestinal obstruction, or malabsorption disorders. A drug that increases fermentation and gas can worsen them. Anyone with a chronic gut condition needs a prescriber to judge whether it is safe at all.

Low blood sugar must be treated with glucose, not table sugar

On its own acarbose rarely causes low blood sugar, but combined with insulin or a sulfonylurea it can. If that happens, the low must be treated with glucose (dextrose). Ordinary table sugar or fruit will not work fast enough, because acarbose slows the breakdown of table sugar into the glucose the body uses quickly. This is a specific safety point a prescriber will explain.

Liver enzymes at higher doses

At higher doses acarbose has been associated with reversible rises in liver enzymes, one reason the dose is capped and monitored. This is a matter for the prescriber, and it resolves when the drug is reduced or stopped.

Off-label use pushes toward the doses with the most side effects

Any use of acarbose for aging, outside diabetes care, is off-label and unstudied, and interest in a bigger effect tends to push toward higher doses. Higher doses are where flatulence and diarrhea are worst and where the reversible liver-enzyme rises appear. That trade-off is what a person would actually be choosing.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Does acarbose extend lifespan?

In mice, it does, and the finding is unusually solid. In the NIA Interventions Testing Program acarbose extended median lifespan in genetically diverse mice. The effect was much larger in males than females, and it was replicated at higher doses. In people, it has not been shown to extend lifespan or healthspan. No completed human longevity trial exists, so the accurate summary is a striking and replicated animal result with no human confirmation yet.

Why is the effect stronger in male mice?

That sex difference is not fully explained. Across the Interventions Testing Program, acarbose extended male mouse lifespan far more than female, and a later higher-dose study confirmed the pattern. Researchers suspect it involves differences in how males and females metabolize the drug and how it acts in the gut. The mechanism behind the sex gap is not established. It is one more reason the mouse result cannot be read straight across to people of either sex.

Does acarbose protect the heart?

The better evidence says no. The idea comes from the STOP-NIDDM trial, which reported fewer cardiovascular events. That result rested on a small number of events in a secondary analysis and was widely questioned. The ACE trial was designed to test it directly in more than six thousand people with established heart disease and prediabetes. In that trial acarbose produced no reduction in cardiovascular events, while confirming that it reduced the onset of diabetes.

What are the main side effects?

They are almost all digestive. Flatulence, bloating, abdominal discomfort and diarrhea are common, because the drug leaves carbohydrate to ferment in the colon, and they are the usual reason people stop taking it. They tend to be worst early and after high-starch meals and often ease with a slow dose increase. At higher doses acarbose has also been linked to reversible rises in liver enzymes. That is part of why the dose is capped and monitored.